Evidence map›Paper›PMID 39568039›Full record

ArticleOrphanet journal of rare diseases2024

Risdiplam: therapeutic effects and tolerability in a small cohort of 6 adult type 2 and type 3 SMA patients.

Gianmarco Severa, Maria Del Carmen Alfaro, Christophe Alimi Ichola, Hussein Shoaito, Sarah Souvannanorath, François-Jerôme Authier, Edoardo Malfatti

Abstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gianmarco SeveraReference Center for Neuromuscular Disorders, AP-HP Henri Mondor University Hospital, 1 Rue Gustave Eiffel, Créteil, 94010, France.
Maria Del Carmen AlfaroInstituto Nacional de Ciencias Neurológicas, Lima, Perú.
Christophe Alimi IcholaReference Center for Neuromuscular Disorders, AP-HP Henri Mondor University Hospital, 1 Rue Gustave Eiffel, Créteil, 94010, France.
Hussein ShoaitoReference Center for Neuromuscular Disorders, AP-HP Henri Mondor University Hospital, 1 Rue Gustave Eiffel, Créteil, 94010, France.
Sarah SouvannanorathReference Center for Neuromuscular Disorders, AP-HP Henri Mondor University Hospital, 1 Rue Gustave Eiffel, Créteil, 94010, France.
François-Jerôme AuthierReference Center for Neuromuscular Disorders, AP-HP Henri Mondor University Hospital, 1 Rue Gustave Eiffel, Créteil, 94010, France.
Edoardo MalfattiReference Center for Neuromuscular Disorders, AP-HP Henri Mondor University Hospital, 1 Rue Gustave Eiffel, Créteil, 94010, France. edoardo.malfatti@aphp.fr.ORCID 0000-0001-7871-8600

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRisdiplam is a validated treatment for adult SMA patients, but clear guidelines concerning functional assessment at baseline and during the follow-up are still limited, especially in terms of sensible and validated outcome measures able to capture minimal changes in motor performances induced by therapy. The aim of this work is to describe the effect of Risdiplam on a cohort of 6 adult type 2 and type 3 SMA patients, using Motor Function Measure (MFM32) as a standardized scaleto quantify the motor improvements induced by therapy.

resultsRisdiplam at the dose of 5 mg/daily was administered to a population of 6 (4 F;2 M) type 2 (N = 4) and type 3 (N = 2), adult SMA patients. Two patients were previously treated by Nusinersen, later suspended due to side effects. At baseline, all patients received a neuromuscular evaluation and a MFM32 assessment. After the beginning of treatment, we evaluated MFM32, patient reported outcomes (PROs), and adverse events over 7-27 months of follow-up. The MFM32 showed an increased score ranging from + 2.16% to + 7.29% in 4 patients. The improvement was maintained overtime, with two patients presenting the longest follow-up period of 24 and 27 months respectively. Subdomain D3 was ameliorated in 66.6% of patients. Two patients previously treated with Nusinersen maintained the pre-Risdiplam scores. The HFMSE was also performed and failed to show significant improvements after treatment. All patients reported subjective ameliorations. The commonest PROs were improvements in breath fatigue, voice's intelligibility, hand strength and dexterity. Adverse effects were mild and decreased over time.

conclusionsRisdiplam is a well-tolerated treatment in our cohort of adult type 2 and type 3 SMA patients and resulted in improvement or stabilization in motor functions. MFM32 proved to be sensitive to detect changes induced by therapy. Subjective meaningful improvements were sustained overtime especially in bulbar functions, breath fatigue and distal motor abilities.

Indexed as

PyrimidinesAdultAzo CompoundsCohort StudiesFemaleHumansMaleMiddle AgedMuscular Atrophy, SpinalSpinal Muscular Atrophies of ChildhoodTreatment OutcomeYoung AdultAzo CompoundsPyrimidinesRisdiplamMFM32Outcome measurePROsRisdiplamSMA

Identifiers

PMID39568039
PMCPMC11580475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.